



# **Company Focus**

30 October 2007 | 8 pages

# **Unitech (UNTE.BO)**

# Sell: Strong 2Q, Adds Landbank; but Upsides Priced In

- Strong quarter, but no surprises Unitech's consolidated 2QFY08 revenues and earnings recorded strong growth on a YoY and QoQ basis, largely in-line. This was largely on back of pre-sold volumes at higher price realizations early on. Higher other income - gains on sale of investments (Rs200m) and dividend (Rs120m) and lower tax provisions, also contributed toward this growth.
- Large addition to landbank The company added 1,750 acres of land in Visakhapatnam, a port city in Andhra Pradesh, for developing an integrated township with ~102m sq ft (~22% additional volumes) over a 10-year period. It continues to aggregate land in newer markets, which will be disclosed in due course once complete; hence presently not factored into our estimates.
- Thrust on asset monetization Having monetized part holding in 6 IT Parks early on to UCP the AIM Fund – Unitech is now exploring opportunities to list a business trust in Singapore for some of its IT Park assets (12% of asset portfolio), which are expected to commence leasing over the next 1-2 years; but given the evolving regulatory issues, timing remains uncertain.
- Raising target to Rs314 This is based on a 15% premium on our increased NAV of Rs273 (vs. Rs215 based on Mar'07 earlier) as we roll forward to Mar'08 and factor in the landbank addition at Vishakhapatnam - adds ~Rs21 to NAV.
- Maintain Sell (3M) As stock trades at 37% premium significantly higher than our 15% premium and our increased TP; we believe upsides are priced in.

Sell/Medium Risk	3M
Price (30 Oct 07)	Rs374.40
Target price	Rs314.00
from Rs247.50	
Expected share price return	-16.1%
Expected dividend yield	0.1%
Expected total return	-16.1%
Market Cap	Rs607,792M
	US\$15,448M

Price Pe	riormand	e (KIG: UN	IE.BU, BB:	UI IN)
INR				
350				٨
300			^ .	Γ'.
250	_	,	$\wedge \wedge \wedge$	
200	$\sim$	7 N M		•
150		V W		
	29 Dec	30 Mar	29 Jun	28 Sep

Drice Derformance (DIC, HNTE DO DD, HT IN)

Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/B	ROE	Yield
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)
2006A	841	0.52	152.0	nm	nm	36.9	0.0
2007A	13,058	8.04	na	46.5	30.5	115.9	0.1
2008E	16,374	10.09	25.4	37.1	16.9	58.6	0.1
2009E	27,542	16.97	68.2	22.1	9.6	55.7	0.1
2010E	41,908	25.82	52.2	14.5	5.8	50.0	0.1

See Appendix A-1 for Analyst Certification and important disclosures.

Source: Powered by dataCentral

# Ashish Jagnani<sup>1</sup>

+91-22-6631-9861 ashish.jagnani@citi.com

#### Aditya Narain, CFA1

+91-22-6631-9879 aditya.narain@citi.com

Karishma Solanki<sup>1</sup> karishma.solanki@citi.com

Citi Investment Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. <sup>1</sup>Citigroup Global Markets India Private Limited

Fiscal year end 31-Mar	2006	2007	2008E	2009E	2010E
Valuation Ratios					
P/E adjusted (x)	nm	46.5	37.1	22.1	14.5
P/E reported (x)	nm	46.5	37.1	22.1	14.5
P/BV (x)	nm	30.5	16.9	9.6	5.8
Dividend yield (%)	0.0	0.1	0.1	0.1	0.1
Per Share Data (Rs)					
EPS adjusted	0.52	8.04	10.09	16.97	25.82
EPS reported	0.52	8.04	10.09	16.97	25.82
BVPS	1.60	12.29	22.11	38.83	64.39
NAVps ordinary	na	na	na	na	na
DPS	0.12	0.29	0.25	0.25	0.25
Profit & Loss (RsM)					
Net operating income (NOI)	2,427	19,565	29,435	46,495	69,064
G&A expenses	-1,077	0	-2,981	-3,459	-5,116
Other Operating items	-110	-66	-231	-289	-550
EBIT including associates	1,240	19,499	26,222	42,747	63,399
Non-oper./net int./except.	152	-1,567	-3,481	-3,956	-4,373
Pre-tax profit	1,392	17,933	22,741	38,791	59,025
Tax	-513	-4,864	-6,368	-11,249	-17,117
Extraord./Min. Int./Pref. Div.	-38	-11	10.074	07.540	41 000
Reported net income	841	13,058	16,374	27,542	41,908
Adjusted earnings	841	13,058	16,374	27,542	41,908
Adjusted EBIT	1,238 1,350	19,485	26,222 26,454	42,747 43,036	63,399 63,949
Adjusted EBITDA	1,550	19,565	20,434	45,050	03,949
Growth Rates (%)					
NOI	95.1	706.1	50.4	58.0	48.5
EBIT adjusted	211.5	nm	34.6	63.0	48.3
EPS adjusted	152.0	nm	25.4	68.2	52.2
Cash Flow (RsM)					
Operating cash flow	-2,165	-21,520	10,539	8,922	9,554
Depreciation/amortization	113	80	231	289	550
Net working capital	-2,180	-46,788	7,234	-19,634	-33,674
Investing cash flow	-3,127	-7,229	-5,608	-5,292	-6,852
Capital expenditure	-3,485	-2,826	-5,608	-5,292	-6,852
Acquisitions/disposals	0 <b>6,474</b>	0 <b>35,077</b>	0 <b>104</b>	0 <b>1,962</b>	0 <b>2,020</b>
Financing cash flow Borrowings	6,686	29,356	510	2,368	2,426
Dividends paid	-188	29,330 -477	-406	-406	-406
Change in cash	1,182	6,328	<b>5,035</b>	<b>5,592</b>	4,722
Balance Sheet (RsM)					
Total assets	44,522	130,900	131,815	180,846	238,005
Cash & cash equivalent	3,899	10,227	15,262	20,854	25,576
Net fixed assets	4,887	8,148	12,904	17,907	23,939
Total liabilities	41,688	110,944	95,905	117,800	133,458
Total Debt	10,449	39,805	40,315	42,683	45,109
Shareholders' funds	2,834	19,956	35,910	63,045	104,548
Profitability/Solvency Ratios					
EBIT margin adjusted (%)	13.9	60.1	48.4	49.4	49.6
ROE adjusted (%)	36.9	115.9	58.6	55.7	50.0
ROA adjusted (%)	2.4	14.9	12.5	17.6	20.0
Net debt to equity (%)	231.1	148.2	69.8	34.6	18.7
Interest coverage (x)	2.9	6.5	6.1	8.6	11.6

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at CitiResearchDataServices@citigroup.com or +852-2501-2791



# **Key Points**

# Strong 2Q, but no surprises

Figure 1. Unitech Consolidated 2QFY08 and 1HFY08 Earnings Summary (Rs Millions)

	1QFY08	2QFY07	2QFY08	YoY	QoQ	1HFY07	1HFY08	YoY
Sales	8,656	4,306	10,135	135%	17%	7,348	18,843	156%
EBITDA	5,005	1,411	5,071	259%	1%	2,209	10,128	358%
EBITDA Mgn (%)	57.8%	32.8%	50.0%			30.1%	53.8%	
Interest	601	216	790	265%	31%	363	1,391	284%
Other Income	341	98	508	419%	49%	496	796	61%
Depreciation	32	17	30	78%	-5%	31	62	102%
PBT	4,714	1,275	4,759	273%	1%	2,312	9,472	310%
PAT	3,667	1,034	4,099	296%	12%	1,807	7,766	330%
PAT after Minority Int & Assoc	3,657	1,030	4,101	298%	12%	1,800	7758	331%

Source: Company Reports, Citi Investment Research

# Landbank addition, increases NAV Estimate

We are increasing our NAV estimate for Unitech to Rs273 (compared to Rs215 earlier) factoring in the large land bank addition in Visakhapatnam and roll forward to Mar '08 (vs. Mar'07 earlier). Our revised NAV estimate is based on a development volume of 561m sq ft compared to ~471m sq ft earlier.

### Large acquisition at Visakhapatnam

Unitech recently acquired 1,750 acres of land at Kapuluppada near Visakhapatnam, a port city, from Andhra Pradesh Industrial Infrastructure Corporation (APIIC) for development of 'Vizag Knowledge City'. As per the arrangement, Unitech will be required to pay a total of Rs.32.9bn over a 10-year period for the land parcel, which on an NPV basis (using discount rate of 14%) is an outflow of ~Rs.17bn as per our estimates. The Knowledge City will be an integrated eco-friendly township with environment friendly apartments, office space, hotels, shopping complexes and facilities for leisure tourism. The project will have a total saleable area of ~102m sq ft being a mix of villas, residential apartments, IT Parks, retail space, hotels and other utilities, which will be developed over a period of 10 years. We expect this project to add ~22% additional volumes and foresee it contributing ~Rs.21 per share to our NAV estimate.

# Thrust on monetizing assets, but timing still uncertain

With Unitech's initial success in monetizing part of its 6 IT parks early on to UCP, the AIM Fund – it is now exploring opportunities to sell more of its IT Park/IT SEZ assets in strategic locations such as Gurgaon, Noida, Kolkata, which are expected to commence leasing over the next 1-2 years to sponsored Trusts/REITs listed in Singapore. This, we believe, should provide Unitech with some benefit from the cap rate compression and boost cash flows. However, the timing of these structures materializing still remains uncertain given the evolving regulatory issues.

Increasing our NAV estimate to Rs273 (vs. Rs215 earlier) as development volume increases to 561m sq ft

#### Figure 2. Visakhapatnam Land Development Summary

	Acres
Villas	400
Apartments	600
IT Park	65
Hotels & Resorts	10
Retail	20
Golf Course	105
Schools, Hospitals, Roads	550
Total	1,750
Source: Company Reports, CIR	

Exploring opportunities to sell more assets to sponsored Trusts/REITs – but timing uncertain, given the evolving regulatory issues

Management, plans to grow the telecom business; but probability of new players getting spectrum is remote

# Other developments

- Develop 28 hotels (~5000 rooms) across key cities Construction is already ongoing on 4 properties. Unitech could potentially look at early asset sales once the projects are close to getting operational.
- Plans to scale up presence in telecoms Unitech has submitted an application to DoT for a Unified Access Service license in 22 circles. As per the management, this is in-line with its plans to grow the telecom business, apart from its existing telecom tower manufacturing for operators such as Hutch (now Vodafone). However, as per our telecom analyst the ability for new players to get spectrum appears remote, given the shortage of spectrum. That said, should it be able to get any spectrum, we could see significant value being created from this business but given the uncertainty, we have not built any upside from this into our estimates.

# Unitech

## Company description

Unitech is one of India's largest, most diversified real estate developers with an emerging pan-India presence. It enjoys leadership in markets of NCR and Kolkata. Its core strengths of land acquisition, reputation in building townships and relationships with governments and customers have enabled it to build a diversified portfolio. Unitech has a land bank of 12,511 acres with a total saleable area of ~593m sq ft spread over Chennai (19%), NCR (16%), Kolkata (16%) and Tier III cities (44%). Residential projects account for about 77% of the saleable area, commercial 5%, IT Parks 7% and retail 5%. In addition, it also has a small presence in power transmission, prefabricated construction, paving block and ready mix concrete. The promoter family holds a 75% stake in the company.

## Investment strategy

We rate Unitech Sell/Medium Risk (3M) rating with a higher target price of Rs314 (vs. Rs247.5 earlier). Our increased target is based on a 15% premium to our revised NAV estimate of Rs273 per share. Recent efforts to monetize six of its IT parks by selling stakes to a REIT has provided it with healthy cash flows – and we expect more such structures going forward, but timing remains uncertain. Additionally, initiatives to reduce concentration in NCR and introduce new revenue streams from lease/management fees are positive. However, management's development plan of ~593mn sq ft is aggressive and does raise execution risks. We forecast an exponential growth in profitability from FY07-10E. With stock already trading at 37% premium significantly higher than our 15% premium, we believe valuations do not leave any margin for error from potential execution delays; upsides seem priced in, in our view.

#### **Valuation**

We increase our target price to Rs314 (vs. Rs247.5 earlier) based on a 15% premium to our increased NAV of Rs273 – due to large land-bank addition at Vishakapatnam (which translates to ~22% additional volumes) and roll forward to Mar'08E (vs. Mar'07 earlier). The 15% premium is based on high valuation

#### Figure 3. NAV Summary (Rs Millions)

Source: Citi Investment Research

Gross NAV of Residential	517,161
Gross NAV of Non-Residential	277,974
Gross Total NAV	795,134
Less: Amt outstanding for land	52,085
Less: Tax @ 28%	208,054
Less: Debt Outstanding	57,194
Less: Customer Advances	48,230
Add: Cash	13,927
Net NAV	443,498
No. of Shares Outstanding (Millions)	1623
NAV Per Share (Rupees)	273

benchmarks for Tier-I developers and recognizing Unitech's - 1) competitive advantage of large diversified land bank, while peers are still aggregating land 2) dynamic business model with thrust on recycling capital faster; 3) strong brand positioning and proven track record. However, this is lower than the 25% premium we ascribe to DLF due to its - higher gearing towards commercial assets, ability to leverage on asset holding company for boosting cash flows and increased leasing income.

Our NAV estimate of Rs273 is based on the following assumption: a) current market price levels to sustain with no price inflation; b) development volume of 561m sq ft (~32m sq ft recognized as revenue up to FY08) c) all projects undertaken will be completed largely as per schedule though, we expect risk of delays; d) average cost of capital of 14%; and e) tax rate of 28%. With stock already trading at a significant premium to NAV, above our estimate we believe upsides are priced in at current valuations.

#### Risks

We rate Unitech Medium Risk. Key reasons for Medium Risk rating are: 1) low-risk/high-return business model 2) pan-India land bank with initiatives to reduce weightage on NCR 3) relatively healthy cash flows. Main company-specific risks include: 1) Developments on monetization of retail and hotel assets similar to IT Parks, could result in healthy cash flows and should positively drive profitability and valuations 2) any developments providing higher visibility on execution of large SEZ projects not included in our NAV estimate is likely to create long-term value 3) Any interest rate reversals, would positively impact earnings growth assumption. If any of these risk factors plays out, Unitech's share price is likely to have difficulty attaining our target price.

# Appendix A-1

## **Analyst Certification**

Each research analyst(s), strategist(s) or research associate(s) responsible for the preparation and content of this research report hereby certifies that, with respect to each issuer or security that the research analyst, strategist or research associate covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each research analyst(s) strategist(s) or research associate(s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst, strategist or research associate in this research report.

#### IMPORTANT DISCLOSURES



Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research product ("the Product"), please contact Citi Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Investment Research Ratings Distribution			
Data current as of 30 September 2007	Buy	Hold	Sell
Citi Investment Research Global Fundamental Coverage (3358)	50%	38%	12%
% of companies in each rating category that are investment banking clients	53%	55%	42%

#### **Guide to Fundamental Research Investment Ratings:**

Citi Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

**Investment ratings** are a function of Citi Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

Guide to Corporate Bond Research Credit Opinions and Investment Ratings:

Citi Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings. CBR risk ratings are approximately equivalent to the following matrix: Low Risk Triple A to Low Double A; Low to Medium Risk High Single A through High Triple B; Medium to High Risk Mid Triple B through High Double B; High to Speculative Risk Mid Double B and Below. The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed income security issued by a company is held to maturity, based upon both fundamental and market risk factors. Certain reports published by Citi Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk ratings. Investment ratings are a function of Citi Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight the bond is expected to outperform the relevant Citigroup bond market sector index (Broad Investment Grade, High Yield Market or Emerging Market), performances of which are updated monthly and can be viewed at http://sd.ny.ssmb.com/ using the "Indexes" tab; Hold/Neutral Weight the bond is expected to perform in line with the relevant Citigroup bond market sector index; or Sell/Underweight the bond is expected to underper

#### OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 30 October 2007 03:58 PM on the issuer's primary market.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citi Smith Barney Ptv Ltd. (ABN 19 009 145 555 and AFSL No. 240813). Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários. BACEN - Brazilian Central Bank. APIMEC - Associação Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA. which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency

(BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. If the Product was prepared by Citi Investment Research and distributed in Japan by Nikko Citigroup Limited ("NCL"), it is being so distributed under license. If the Product was prepared by NCL and distributed by Nikko Cordial Securities Inc. or Citigroup Global Markets Inc. it is being so distributed under license. NCL is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. In the event that an error is found in an NCL research report, a revised version will be posted on Citi Investment Research's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor, Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

This Product is not intended for distribution in Poland. Any receipt or review of the Product in Poland is not authorized by the Firm.

© 2007 Citigroup Global Markets Inc. (© Nikko Citigroup Limited, if this Product was prepared by it). Citi Investment Research is a division and service marks of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST